Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

Nanjo S, Bivona TG

Journal of Thoracic Disease

November 01, 2018

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.

Program:
CTD²
Last updated: February 07, 2019